Longer Duration of Treatment with ICIs Associated with a Higher Rate of Complete Response Among Patients with MMRd Cancers By Ogkologos - March 5, 2025 22 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a systematic review of published studies Source RELATED ARTICLESMORE FROM AUTHOR Manageable Safety Profile and Antitumour Activity of Zongertinib in Pretreated Patients with HER2-altered Tumours, Including NSCLC EMA Recommends Extension of Therapeutic Indications for Nivolumab and Ipilimumab to Unresectable or Advanced HCC ESMO Sarcoma and Rare Cancers Congress 2025, Lugano, Switzerland, 20-22 March MOST POPULAR Talk Cancer: How to have conversations that could save lives April 13, 2021 Our COVID-19 Response: How GreaterGood Is Making An Impact During The... April 23, 2020 37-Year-Old Mom Breaks American Marathon Record January 21, 2022 Triple negative breast cancer drug given initial ‘no’ for NHS in... April 8, 2022 Load more HOT NEWS FDA Approves Sacituzumab Govitecan-hziy for HR-positive Advanced Breast Cancer Efficacy and Safety of Trastuzumab Deruxtecan in Exploratory Cohorts of Patients... A Chemotherapy-Free Regimen of Tucatinib and Trastuzumab Shows Antitumour Activity with... Cancer Clinical Trials Bounce Back After Significant COVID-19 Disruption: Data From...
